491 related articles for article (PubMed ID: 16372821)
1. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting.
Gökalp O; Gunes A; Cam H; Cure E; Aydın O; Tamer MN; Scordo MG; Dahl ML
Eur J Clin Pharmacol; 2011 Dec; 67(12):1223-9. PubMed ID: 21691805
[TBL] [Abstract][Full Text] [Related]
5. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
6. Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals.
Yin SJ; Qi HM; Wang X; Zhang P; Lu Y; Wei MJ; Li P; Qi GZ; Lou YQ; Lu C; Zhang GL
Pharmacogenet Genomics; 2017 Apr; 27(4):125-134. PubMed ID: 28099407
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients.
Surendiran A; Pradhan SC; Agrawal A; Subrahmanyam DK; Rajan S; Anichavezhi D; Adithan C
Eur J Clin Pharmacol; 2011 Aug; 67(8):797-801. PubMed ID: 21336994
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
Wang B; Wang J; Huang SQ; Su HH; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
[TBL] [Abstract][Full Text] [Related]
11. Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
13. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
14. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
He SM; Zhou ZW; Li XT; Zhou SF
Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
Cheng Y; Wang G; Zhang W; Fan L; Chen Y; Zhou HH
Eur J Clin Pharmacol; 2013 Mar; 69(3):407-13. PubMed ID: 22842957
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Scheen AJ
Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
[TBL] [Abstract][Full Text] [Related]
20. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.
Yasar U; Lundgren S; Eliasson E; Bennet A; Wiman B; de Faire U; Rane A
Biochem Biophys Res Commun; 2002 Nov; 299(1):25-8. PubMed ID: 12435384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]